Cargando…

Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy

Radiotherapy for prostate cancer is associated with an increased incidence of secondary bladder cancer (BC). We investigated the incidence, clinicopathological characteristics, and prognosis of BC after radiotherapy, surgical therapy, and primary androgen-deprivation therapy (ADT) for prostate cance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shiota, Masaki, Yokomizo, Akira, Takeuchi, Ario, Imada, Kenjiro, Kiyoshima, Keijiro, Inokuchi, Junichi, Tatsugami, Katsunori, Ohga, Saiji, Nakamura, Katsumasa, Honda, Hiroshi, Naito, Seiji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546499/ https://www.ncbi.nlm.nih.gov/pubmed/25900243

Ejemplares similares

Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone
por: Akitake, Naoko, et al.
Publicado: (2018)

Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer
por: Kashiwagi, Eiji, et al.
Publicado: (2020)

Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy
por: Shiota, Masaki, et al.
Publicado: (2018)

Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer
por: Hirata, Yu, et al.
Publicado: (2019)

Equol inhibits prostate cancer growth through degradation of androgen receptor by S‐phase kinase‐associated protein 2
por: Itsumi, Momoe, et al.
Publicado: (2016)

Collateral resistance to taxanes in enzalutamide‐resistant prostate cancer through aberrant androgen receptor and its variants
por: Shiota, Masaki, et al.
Publicado: (2018)

Acute urinary morbidity after a permanent (125)I implantation for localized prostate cancer
por: Ohga, Saiji, et al.
Publicado: (2014)

Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
por: Yamada, Shigetomo, et al.
Publicado: (2022)

Gene amplification of YB‐1 in castration‐resistant prostate cancer in association with aberrant androgen receptor expression
por: Shiota, Masaki, et al.
Publicado: (2020)

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
por: Uemura, Hiroji, et al.
Publicado: (2021)

Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors
por: Matsumoto, Takashi, et al.
Publicado: (2021)

Androgen Deprivation Therapy and Cardiovascular Risk
por: Mourmouris, Panagiotis, et al.
Publicado: (2012)

Metabolic effects of androgen deprivation therapy
por: Choi, See Min, et al.
Publicado: (2015)

Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)

CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
por: Boban, Marko
Publicado: (2019)

Cardiovascular Toxicity of Androgen Deprivation Therapy
por: Boland, Julia, et al.
Publicado: (2021)

Persistent Testosterone Suppression After Cessation of Androgen Deprivation Therapy for Prostate Cancer
por: Delgado, Jessica, et al.
Publicado: (2022)

Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score
por: Akaza, Hideyuki, et al.
Publicado: (2013)

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
por: Stensland, Kristian D, et al.
Publicado: (2022)

Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer
por: Nam, Wook, et al.
Publicado: (2018)

Testicular recurrence of oligometastatic prostatic adenocarcinoma after 22 years of androgen deprivation therapy
por: Fortier, Alexa, et al.
Publicado: (2022)

Nomogram for predicting the biochemical recurrence of prostate cancer after neoadjuvant androgen deprivation therapy
por: Sun, Qi, et al.
Publicado: (2023)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Androgen deprivation therapy increases brain ageing
por: Plata-Bello, Julio, et al.
Publicado: (2019)

Androgen Deprivation Therapy–Induced Cardiovascular Disease
por: Dhanushkodi, Manikandan
Publicado: (2016)

Androgen deprivation therapy and the risk of subsequent keratitis
por: Liu, Dai-Wei, et al.
Publicado: (2020)

Androgen deprivation therapy as backbone therapy in the management of prostate cancer
por: Merseburger, Axel S, et al.
Publicado: (2016)

Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy
por: Shinohara, Nobuo, et al.
Publicado: (2015)

Successful management of cryptococcosis of the bilateral adrenal glands and liver by unilateral adrenalectomy with antifungal agents: a case report
por: Matsuda, Yayoi, et al.
Publicado: (2011)

Efficacy of zoledronic acid in older prostate cancer patients undergoing androgen deprivation therapy
por: Kojima, Ippei, et al.
Publicado: (2019)

Solitary Leptomeningeal Recurrence From Prostate Adenocarcinoma After Treatment With Cytotoxic Gene Therapy, Radiation Therapy, and Androgen Deprivation Therapy
por: Chevli, Neil, et al.
Publicado: (2021)

Early upregulation of AR and steroidogenesis enzyme expression after 3 months of androgen-deprivation therapy
por: Hamid, Agus Rizal A. H., et al.
Publicado: (2020)

Influence of Baseline Cardiovascular Comorbidities on Mortality after Androgen Deprivation Therapy for Metastatic Prostate Cancer
por: Wu, Szu-Yuan, et al.
Publicado: (2020)

Testosterone Recovery after Androgen Deprivation Therapy in Prostate Cancer: Building a Predictive Model
por: Borque-Fernando, Ángel, et al.
Publicado: (2023)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy prevents bladder cancer recurrence
por: Izumi, Koji, et al.
Publicado: (2014)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dbj9btnluverun9bghls7njue0